GlassScriptPhysician profile
Nagwa Ibrahim
NPI 1790297638
$3,691.35
in general payments reported to CMS, 2019-2025
11 companies · $1,276 in 2025
The $1,276 reported for 2025 was more than what 94% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,862 · 2020: $39.54 · 2021: $150 · 2022: $125 · 2024: $239 · 2025: $1,276.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,516.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,515.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,814.83 | 2019-2025 | Precision7, Tryptyr, Precision 1 |
| Glaukos Corporation | $453.42 | 2019-2025 | |
| Bausch & Lomb Americas INC. | $427.06 | 2025 | Miebo, Xiidra, Vyzulta |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $319.65 | 2019 | |
| Tarsus Pharmaceuticals, INC. | $253.62 | 2024-2025 | Xdemvy |
| Eyevance Pharmaceuticals LLC | $149.71 | 2021 | |
| Johnson & Johnson Vision Care, INC. | $122.32 | 2025 | Acuvue |
| Visioneering Technologies, INC. | $92.55 | 2019 | |
| Harrow Eye, LLC | $21.04 | 2024 | Vevye |
| Coopervision INC. | $19.91 | 2019 | |
| Carl Zeiss Meditec, INC. | $17.24 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nagwa Ibrahim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.